Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 942
Filter
1.
Pharmacol Res Perspect ; 9(5): e00879, 2021 10.
Article in English | MEDLINE | ID: mdl-34628723

ABSTRACT

The unbound concentrations of 14 commercial drugs, including five non-efflux/uptake transporter substrates-Class I, five efflux transporter substrates-class II and four influx transporter substrates-Class III, were simultaneously measured in rat liver, muscle, and blood via microanalysis. Kpuu,liver and Kpuu,muscle were calculated to evaluate the membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver. For Class I compounds, represented by antipyrine, unbound concentrations among liver, muscle and blood are symmetrically distributed when compound hepatic clearance is low. And when compound hepatic clearance is high, unbound concentrations among liver, muscle and blood are asymmetrically distributed, such as Propranolol. For Class II and III compounds, overall, the unbound concentrations among liver, muscle, and blood are asymmetrically distributed due to a combination of hepatic metabolism and efflux and/or influx transporter activity.


Subject(s)
Cell Membrane/metabolism , Liver/metabolism , Membrane Transport Proteins/metabolism , Muscle, Skeletal/metabolism , Pharmaceutical Preparations/metabolism , Animals , Antipyrine/blood , Antipyrine/metabolism , Atenolol/blood , Atenolol/metabolism , Carbamazepine/blood , Carbamazepine/metabolism , Digoxin/blood , Digoxin/metabolism , Diltiazem/blood , Diltiazem/metabolism , Diphenhydramine/blood , Diphenhydramine/metabolism , Drug Elimination Routes , Gabapentin/blood , Gabapentin/metabolism , Lamotrigine/blood , Lamotrigine/metabolism , Memantine/blood , Memantine/metabolism , Microdialysis , Ofloxacin/blood , Ofloxacin/metabolism , Pharmaceutical Preparations/blood , Propranolol/blood , Propranolol/metabolism , Pyrilamine/blood , Pyrilamine/metabolism , Quinidine/blood , Quinidine/metabolism , Rats , Terfenadine/analogs & derivatives , Terfenadine/blood , Terfenadine/metabolism
2.
Forensic Sci Int ; 327: 110978, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34481114

ABSTRACT

Propranolol is a widely used beta-blocker mainly prescribed for the treatment of hypertension and other cardiac conditions. This medicine is also a frequent finding in drug screens, but little is known about its post-mortem toxicological profile. Our aim was to examine all post-mortem toxicology cases positive for propranolol in a three-year period, between 2016 and 2018 in Finland, and to compare these cases to those positive for metoprolol, another beta-blocker commonly used to treat cardiac diseases. There were 179 cases positive for propranolol and 416 for metoprolol in the study period. In the majority of propranolol cases (53%), the drug concentration in the blood was above the typical therapeutic range, but among the metoprolol cases this proportion was 18%. Propranolol was significantly more common than metoprolol in fatal poisonings, suicides and in cases with a history of drug abuse. Alcohol, benzodiazepines, antipsychotics and antidepressants were significantly more often detected in propranolol cases than in metoprolol cases. The deceased positive for propranolol were significantly younger than those positive for metoprolol. Cardiovascular diseases as the underlying cause of death were significantly more common among the metoprolol cases than among the propranolol cases. Our results showed significant differences between the propranolol group and the metoprolol group in post-mortem toxicology cases. The two drugs were used by two very different groups of people, with propranolol use being associated with psychiatric conditions.


Subject(s)
Adrenergic beta-Antagonists/blood , Databases, Factual , Forensic Toxicology/statistics & numerical data , Metoprolol/blood , Propranolol/blood , Adult , Age Distribution , Aged , Aged, 80 and over , Cardiovascular Diseases/epidemiology , Cause of Death , Female , Finland/epidemiology , Humans , Male , Mental Disorders/epidemiology , Middle Aged , Substance Abuse Detection/statistics & numerical data
3.
Eur J Pharmacol ; 882: 173287, 2020 Sep 05.
Article in English | MEDLINE | ID: mdl-32585157

ABSTRACT

Expression of the ß-myosin heavy chain (ß-MHC), a major component of the cardiac contractile apparatus, is tightly regulated as even modest increases can be detrimental to heart under stress. In healthy hearts, continuous inhibition of ß-adrenergic tone upregulates ß-MHC expression. However, it is unknown whether the duration of the ß-adrenergic inhibition and ß-MHC expression are related. Here, we evaluated the effects of intermittent ß-blockade on cardiac ß-MHC expression. To this end, the ß-blocker propranolol, at the dose of 15mg/kg, was administered once a day in mice for 14 days. This dosing schedule caused daily drug-free periods of at least 6 h as evidenced by propranolol plasma concentrations and cardiac ß-adrenergic responsiveness. Under these conditions, ß-MHC expression decreased by about 75% compared to controls. This effect was abolished in mice lacking ß1- but not ß2-adrenergic receptors (ß-AR) indicating that ß-MHC expression is regulated in a ß1-AR-dependent manner. In ß1-AR knockout mice, the baseline ß-MHC expression was fourfold higher than in wild-type mice. Also, we evaluated the impact of intermittent ß-blockade on ß-MHC expression in mice with systolic dysfunction, in which an increased ß-MHC expression occurs. At 3 weeks after myocardial infarction, mice showed systolic dysfunction and upregulation of ß-MHC expression. Intermittent ß-blockade decreased ß-MHC expression while attenuating cardiac dysfunction. In vitro studies showed that propranolol does not affect ß-MHC expression on its own but antagonizes catecholamine effects on ß-MHC expression. In conclusion, a direct relationship occurs between the duration of the ß-adrenergic inhibition and ß-MHC expression through the ß1-AR.


Subject(s)
Adrenergic beta-Antagonists/pharmacology , Myocardium/metabolism , Myosin Heavy Chains/genetics , Propranolol/pharmacology , Receptors, Adrenergic, beta/genetics , Ventricular Myosins/genetics , Adrenergic beta-Agonists/pharmacology , Adrenergic beta-Antagonists/blood , Adrenergic beta-Antagonists/pharmacokinetics , Adrenergic beta-Antagonists/therapeutic use , Animals , Down-Regulation/drug effects , Female , Isoproterenol/pharmacology , Male , Mice, Inbred C57BL , Mice, Knockout , Myocardial Infarction/drug therapy , Myocardial Infarction/genetics , Myocardial Infarction/pathology , Propranolol/blood , Propranolol/pharmacokinetics , Propranolol/therapeutic use
4.
Article in English | MEDLINE | ID: mdl-32371329

ABSTRACT

High-performance liquid chromatography (HPLC) and solid phase micro membrane tip extraction (SPMMTE) methods are developed for the simultaneous analysis of eleven cardiovascular drugs in human plasma. Iron nanoparticles were obtained by the green method, characterized by XRD, FT-IR, TEM, and EDS and utilized in SPMMTE for sample preparation. The mobile phase used was ammonium acetate buffer-methanol-acetonitrile (65:18:17) with a 1.0 mL/min flow rate at 260 nm detection. Column used was Sunshell C18 150 × 4.6 mm, 2.6 µm. The values of k, α, and Rs were ranged from 040 to109.22, 1.20 to 2.67 and 1.0 to 26.18. SPMMTE and HPLC methods were fast, reproducible, precise, robust, economic and rugged for analysis of methyldopa, hydrochlorothiazide, prazosin hydrochloride, furosemide, labetalol, propranolol, valsartan, losartan potassium, diltiazem, irbesartan and spironolactone in human plasma. The recoveries (%) of methyldopa, hydrochlorothiazide, prazosin hydrochloride, furosemide, labetalol, propranolol, valsartan, losartan potassium, diltiazem, irbesartan, and spironolactone were 91.0, 85.2, 92.3, 90.4, 90.1, 85.6, 86.6, 86.2, 85.1, 86.6, and 85.7, respectively. These results showed that SPMMTE and HPLC methods can be applied to test the described drugs in several matrices.


Subject(s)
Antihypertensive Agents/blood , Metal Nanoparticles/chemistry , Nanocomposites/chemistry , Adsorption , Chromatography, High Pressure Liquid , Diltiazem/blood , Furosemide/blood , Humans , Hydrochlorothiazide/blood , Irbesartan/blood , Iron/chemistry , Labetalol/blood , Limit of Detection , Losartan/blood , Methyldopa/blood , Polyvinyl Alcohol/chemistry , Prazosin/blood , Propranolol/blood , Reproducibility of Results , Solid Phase Microextraction , Spironolactone/blood , Valsartan/blood
5.
Bull Exp Biol Med ; 168(4): 465-469, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32146624

ABSTRACT

We studied pharmacokinetics and bioavailability of verapamil, propranolol, and ethacizine in healthy volunteers after single oral administration under normal conditions and on the second day of simulated antiorthostatic hypokinesia modeling some effects of microgravity. Under conditions of antiorthostatic hypokinesia, a tendency to a decrease in half-elimination period, mean retention time, and volume of distribution and an increase in the rate of absorption, ratio of maximum concentrations, and relative rate of absorption of verapamil and propranolol were revealed. For ethacizine, a statistically significant increase in the time of attaining maximum concentration and volume of distribution and a decrease in the maximum concentration, rate of absorption, ratio of maximum concentrations, and relative rate of absorption under conditions of antiorthostatic hypokinesia were found.


Subject(s)
Cardiovascular Agents/pharmacokinetics , Hypokinesia/blood , Phenothiazines/pharmacokinetics , Propranolol/pharmacokinetics , Verapamil/pharmacokinetics , Weightlessness Simulation/methods , Adult , Area Under Curve , Biological Availability , Cardiovascular Agents/blood , Half-Life , Humans , Hypokinesia/drug therapy , Male , Middle Aged , Phenothiazines/blood , Propranolol/blood , Verapamil/blood
6.
Article in English | MEDLINE | ID: mdl-31629310

ABSTRACT

In this paper we present an FDA validated method to analyze ten antiarrhythmic drugs (atenolol, bisoprolol, carvedilol, diltiazem, flecainide, lidocaine, metoprolol, propranolol, sotalol and verapamil). A simple and fast sample preparation protocol with protein precipitation followed by ultra performance liquid chromatography (UPLC) for chromatographic separation and mass spectrometric detection applying electrospray ionization (ESI+) and selected reaction monitoring mode (MS/MS) was used. Only 50 µl plasma sample is needed for the simultaneous quantification of all compounds within a 5 min run-to-run analysis time. Sotalol-D6, carvedilol-D5 and verapamil-D6 were used as internal standards. The method was validated according to the FDA guidelines. Correlation coefficients were higher than 0.998 for all compounds. Intra- and interday accuracies were within 15 CV(%) for all analytes. The method is currently successfully applied for routine analysis in our hospital.


Subject(s)
Anti-Arrhythmia Agents/blood , Tandem Mass Spectrometry/methods , Atenolol/blood , Bisoprolol/blood , Carvedilol/blood , Chromatography, High Pressure Liquid , Diltiazem/blood , Flecainide/blood , High-Throughput Screening Assays/methods , Humans , Lidocaine/blood , Metoprolol/blood , Propranolol/blood , Reproducibility of Results , Sotalol/blood , Spectrometry, Mass, Electrospray Ionization , Verapamil/blood
7.
Eur J Pharm Sci ; 105: 137-143, 2017 Jul 15.
Article in English | MEDLINE | ID: mdl-28502673

ABSTRACT

Propranolol (PROP) undergoes extensive first-pass metabolism by the liver resulting in a relatively low bioavailability (13-23%); thus, multiple oral doses are required to achieve therapeutic effect. Since some studies have reported that glucosamine (GlcN) can increase the bioavailability of some drugs, therefore, it is aimed to study whether GlcN can change the pharmacokinetic parameters of PROP, thus modulating its bioavailability. When PROP was orally co-administered with GlcN (200mg/kg) to rats, PROP area under curve (AUC) and maximum concentration (Cmax) were significantly decreased by 43% (p<0.01) and 33% (p<0.05), respectively. In line with the in vivo results, in silico simulations confirmed that GlcN decreased rat intestinal effective permeability (Peff) and increased PROP clearance by 50%. However, in situ single pass intestinal perfusion (SPIP) experiments showed that GlcN significantly increased PROP serum levels (p<0.05). Furthermore, GlcN decreased PROP disposition/distribution into cultured hepatocytes in concentration dependent manner. Such change in the interaction pattern between GlcN and PROP might be attributed to the environment of the physiological buffer used in the in vitro experiments (pH7.2) versus the oral administration and thus, enhanced PROP permeability. Nevertheless, such enhancement was not detected when everted gut sacks were incubated with both drugs at the same pH in vitro. In conclusion, GlcN decreased PROP serum levels in rats in a dose-dependent manner. Such interaction might be attributed to decreased intestinal permeability and enhanced clearance of PROP in the presence of GlcN. Further investigations are still warranted to explain the in vitro inhibitory action of GlcN on PROP hepatocytes disposition and the involvement of GlcN in the intestinal and hepatic metabolizing enzymes of PROP at different experimental conditions.


Subject(s)
Adrenergic beta-Antagonists/pharmacokinetics , Glucosamine/pharmacology , Intestinal Absorption/drug effects , Propranolol/pharmacokinetics , Administration, Oral , Adrenergic beta-Antagonists/blood , Animals , Biological Availability , Female , Hepatocytes/metabolism , Intestinal Mucosa/metabolism , Male , Propranolol/blood , Rats, Sprague-Dawley
8.
Bioanalysis ; 9(6): 503-515, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28225296

ABSTRACT

AIM: Doxapram, a respiratory stimulant, is used to treat apnea. A reliable method of determining doxapram in blood is required for monitoring purposes. RESULTS: Doxapram, keto-doxapram (active metabolite) and propranolol (internal standard) were extracted from human serum by protein precipitation and plate filtration. Molecular ions were generated by electrospray ionization in positive ion mode, and the ions were analyzed using a triple-quadrupole mass spectrometer. The calibration curves were linear from 20 to 5000 ng/ml. The method was validated and the selectivity, reproducibility and stability met the acceptance criteria. CONCLUSION: An LC-MS/MS method was successfully developed for determining doxapram and keto-doxapram in human serum. The method can be used to monitor doxapram and keto-doxapram concentrations in blood.


Subject(s)
Chromatography, Liquid/methods , Doxapram/analogs & derivatives , Doxapram/blood , Tandem Mass Spectrometry/methods , Calibration , Drug Monitoring , Drug Stability , Humans , Limit of Detection , Propranolol/blood , Reference Standards , Reproducibility of Results
9.
J Burn Care Res ; 38(4): 243-250, 2017.
Article in English | MEDLINE | ID: mdl-28240622

ABSTRACT

The systemic impact of severe burn injury results in a variety of disorders that require therapeutic intervention. Propranolol, a nonselective ß1, ß2-adrenergic receptor antagonist, reduces resting heart rate and cardiac work caused by elevated circulating catecholamines. Oxandrolone, a testosterone mimetic, promotes protein synthesis and anabolism to counter muscle wasting. Coadministration of these drugs is expected to synergistically improve patient outcomes. Testosterone administration is known to alter ß-adrenergic receptor-mediated signaling. Here, we determined whether the coadministration of oxandrolone alters plasma propranolol concentrations. Ninety-two pediatric patients with burns covering ≥30% of the TBSA were enrolled in this institutional review board-approved study and randomized to receive propranolol (n = 49) or oxandrolone + propranolol (n = 43). Plasma propranolol concentrations were determined following two dosing strategies: Q6 (liquid formulation; n = 86) and Q24 (extended-release capsule; n = 22). Samples were drawn before drug administration and at regular intervals throughout the next two dosing periods. Heart rate and blood pressure were recorded throughout the study. Propranolol half-life was 3.3 hours for the Q6 drug dosing frequency (P < .0001) and 11.2 hours for the Q24 strategy (P < .0001). Percentage of predicted heart rate declined by 2.8% for each doubling of the propranolol concentration in the Q6 dosing schedule (P < .0001). Percentage of predicted heart rate declined by 2.5% for each doubling of propranolol concentration on the Q24 dosing schedule (P < .0001). Maximum and minimum propranolol plasma concentrations were similar with either dosing regimen. The addition of oxandrolone did not affect any of the measured parameters. Oxandrolone coadministration does not alter propranolol's plasma concentration, half-life, or effect on heart rate. This study is registered at clincialtrials.gov: NCT00675714.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Anabolic Agents/therapeutic use , Burns/therapy , Oxandrolone/therapeutic use , Propranolol/blood , Propranolol/therapeutic use , Adolescent , Adrenergic beta-Antagonists/blood , Blood Pressure , Burns/blood , Burns/physiopathology , Child , Child, Preschool , Drug Therapy, Combination , Female , Half-Life , Heart Rate , Humans , Male
10.
Pediatr Res ; 81(2): 307-314, 2017 02.
Article in English | MEDLINE | ID: mdl-27814346

ABSTRACT

BACKGROUND: Oral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely. This study evaluated safety and efficacy of propranolol eye micro-drops in preterm newborns with ROP. METHODS: A multicenter open-label trial, planned according to the Simon optimal two-stage design, was performed to analyze safety and efficacy of propranolol micro-drops in newborns with stage 2 ROP. To this end, hemodynamic and respiratory parameters were monitored, and blood samples were collected weekly, for 3 wk. Propranolol plasma levels were also monitored. The progression of the disease was evaluated with serial ophthalmologic examinations. RESULTS: Twenty-three newborns were enrolled. Since the fourth of the first 19 newborns enrolled in the first stage of the study showed a progression to stage 2 or 3 with plus, the second stage was prematurely discontinued. Even though the objective to complete the second stage was not achieved, the percentage of ROP progression (26%) was similar to that obtained previously with oral propranolol administration. However, no adverse effects were observed and propranolol plasma levels were significantly lower than those measured after oral administration. CONCLUSION: Propranolol 0.1% eye micro-drops are well tolerated, but not sufficiently effective. Further studies are required to identify the optimal dose and administration schedule.


Subject(s)
Propranolol/administration & dosage , Retinopathy of Prematurity/drug therapy , Administration, Ophthalmic , Administration, Oral , Administration, Topical , Disease Progression , Female , Hemodynamics , Humans , Infant, Newborn , Male , Neovascularization, Physiologic/drug effects , Patient Safety , Pilot Projects , Propranolol/blood , Respiration
11.
Chirality ; 28(11): 737-743, 2016 11.
Article in English | MEDLINE | ID: mdl-27791319

ABSTRACT

In this study the analysis and confirmation of flumequine enantiomers in rat plasma by ultra-fast liquid chromatography coupled with electron spray ionization mass spectrometry (using propranolol as an internal standard [IS]) was developed and validated. Plasma samples were prepared by liquid-liquid extraction using methyl tert-butyl ether as the extraction solvent. Direct resolution of the R- and S-isomers was performed on a CHIRALCEL OJ-RH column (4.6 × 150 mm, 5 µm) using acetonitrile / 0.1% formic acid / 1 mM ammonium acetate as the mobile phase. Detection was operated by electron spray ionization in the selected ion monitoring and positive ion mode. The target ions at m/z 262.1 and m/z 260.1 were selected for the quantification of the enantiomers and IS, respectively. The linear range was 0.5-500 ng/mL. The precisions (coefficient of variation, CV%) and recoveries were 1.43-8.68 and 94.24-106.76%, respectively. The lowest quantitation limit for both enantiomers is 0.5 ng/mL, which is sensitive enough to be applied to sample analysis in other related studies.


Subject(s)
Chromatography, Liquid/methods , Fluoroquinolones/blood , Fluoroquinolones/chemistry , Spectrometry, Mass, Electrospray Ionization/methods , Tandem Mass Spectrometry/methods , Animals , Liquid-Liquid Extraction , Methyl Ethers/chemistry , Propranolol/blood , Rats , Reproducibility of Results , Stereoisomerism
12.
Article in English | MEDLINE | ID: mdl-26926395

ABSTRACT

Four simple and accurate spectrophotometric methods were proposed for the simultaneous determination of three ß-adrenergic blockade, e.g. atenolol, metoprolol and propranolol. The methods were based on the reaction of the three drugs with erythrosine B (EB) in a Britton-Robinson buffer solution at pH4.6. EB could combine with the drugs to form three ion-association complexes, which resulted in the resonance Rayleigh scattering (RRS) intensity that is enhanced significantly with new RRS peaks that appeared at 337 nm and 370 nm, respectively. In addition, the fluorescence intensity of EB was also quenched. The enhanced scattering intensities of the two peaks and the fluorescence quenched intensity of EB were proportional to the concentrations of the drugs, respectively. What is more, the RRS intensity overlapped with the double-wavelength of 337 nm and 370 nm (so short for DW-RRS) was also proportional to the drugs concentrations. So, a new method with highly sensitive for simultaneous determination of three bisoprolol drugs was established. Finally, the optimum reaction conditions, influencing factors and spectral enhanced mechanism were investigated. The new DW-RRS method has been applied to simultaneously detect the three ß-blockers in fresh serum with satisfactory results.


Subject(s)
Adrenergic beta-Antagonists/blood , Atenolol/blood , Erythrosine/chemistry , Fluorescent Dyes/chemistry , Metoprolol/blood , Propranolol/blood , Adrenergic beta-Antagonists/analysis , Atenolol/analysis , Humans , Light , Limit of Detection , Metoprolol/analysis , Propranolol/analysis , Scattering, Radiation , Spectrometry, Fluorescence/methods , Spectrophotometry/methods
13.
Regul Toxicol Pharmacol ; 76: 21-9, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26773344

ABSTRACT

To investigate the relationship between the pharmacokinetics (PK) and effects and/or side-effects of nifedipine and propranolol, simultaneous examination of their PK and pharmacodynamics (PD), namely blood pressure (BP), heart rate (HR), and QT interval (QT), were assessed in spontaneously hypertensive rats as a disease model. Drugs were infused intravenously for 30 min, then plasma PK and hemodynamic effects were monitored. After general two-compartmental analysis was applied to the plasma data, PD parameters were calculated by fitting the data to PK-PD models. After nifedipine administration, the maximal hypotensive effect appeared about 10 min after starting the infusion, then BP started to elevate although the plasma concentration increased, supposedly because of a negative feedback mechanism generated from the homeostatic mechanism. After propranolol administration, HR decreased by half, and this bradycardic effect was greater than that with nifedipine. Wide variation in QT was observed when the propranolol concentration exceeded 700 ng/mL. This variation may have been caused by arrhythmia. Prolongation of QT with propranolol was greater than that with nifedipine, and bradycardia was slower than the concentration increase and QT prolongation. The characteristically designed PK-PD model incorporating a negative feedback system could be adequately and simultaneously fitted to both observed effect and side-effects.


Subject(s)
Adrenergic beta-Antagonists/pharmacokinetics , Antihypertensive Agents/pharmacokinetics , Blood Pressure/drug effects , Calcium Channel Blockers/pharmacokinetics , Hypertension/drug therapy , Nifedipine/pharmacokinetics , Propranolol/pharmacokinetics , Action Potentials/drug effects , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/blood , Adrenergic beta-Antagonists/toxicity , Animals , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/blood , Antihypertensive Agents/toxicity , Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/blood , Calcium Channel Blockers/toxicity , Disease Models, Animal , Feedback, Physiological , Heart Rate/drug effects , Hypertension/blood , Hypertension/physiopathology , Infusions, Intravenous , Male , Models, Biological , Models, Statistical , Nifedipine/administration & dosage , Nifedipine/blood , Nifedipine/toxicity , Propranolol/administration & dosage , Propranolol/blood , Propranolol/toxicity , Rats, Inbred SHR , Risk Assessment
14.
Curr Drug Deliv ; 13(7): 1144-1151, 2016.
Article in English | MEDLINE | ID: mdl-26666297

ABSTRACT

BACKGROUND: The aim of this study was to determine the concentrations of propranolol in periocular tissues and plasma after ocular instillation of 0.5% propranolol gel-forming solution (GFS) as compared to 0.5% propranolol non-gelforming solution (non-GFS) for potential use in the treatment of periocular capillary hemangiomas. METHODS: A GFS prepared in 1% sodium alginate or a non-GFS in phosphatebuffered saline was instilled into the eyes of rabbits. At predetermined time intervals after dosing, blood was withdrawn, rabbits were euthanized, and periocular tissues were dissected. RESULTS: Ocular instillation of the GFS resulted in higher concentrations of propranolol in the outer layers of both the upper and lower eyelids (in the range of 9.9-36.9 µg/g) and maintained higher levels of propranolol in these tissues for 24 h after dosing, as compared to the ocular instillation of the non-GFS (in the range of 3.4-15.1 µg/g). While the concentrations of propranolol in the other periocular tissues were generally similar for GFS and non-GFS at 1 h after dosing, the concentrations of propranolol in the extraocular muscles and periocular fat were higher for GFS than those for non-GFS between 4-24 h after dosing. Lower level of propranolol in plasma was observed at 1 h with GFS as compared with non-GFS. CONCLUSION: The use of the propranolol gel-forming solution can prolong drug retention on the ocular surface and increase its distribution to the outer layers of the eyelids while decreasing systemic exposure to the drug.


Subject(s)
Adrenergic beta-Antagonists , Eye/metabolism , Ophthalmic Solutions , Propranolol , Administration, Ophthalmic , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/blood , Adrenergic beta-Antagonists/chemistry , Adrenergic beta-Antagonists/pharmacokinetics , Animals , Gels , Male , Ophthalmic Solutions/administration & dosage , Ophthalmic Solutions/chemistry , Ophthalmic Solutions/pharmacokinetics , Propranolol/administration & dosage , Propranolol/blood , Propranolol/chemistry , Propranolol/pharmacokinetics , Rabbits
15.
Aviakosm Ekolog Med ; 50(5): 5-10, 2016.
Article in English, Russian | MEDLINE | ID: mdl-29553588

ABSTRACT

Purpose of the work was to study pharmacokinetics of beta adrenoblocker propranolol, and hemodynamic indices in volunteers for simulation of some effects of microgravity The study involved 8 essentially healthy subjects and the head-down tilt (-80) bedrest model reproducing the effects of microgravity (BD). This was designed as three series of investigations, i.e. before BD, on BD day-2 and on the first day of BD completion. Propranolol concentration in blood plasma was determined using high performance liquid chromatography with fluorescence detection. Hemodynamic indices including heart rate (HR), stroke volume, cardiac output, cardiac index and total peripheric resistance were measured using integral rheography; average blood pressure (BPav) Was assessed by Korotkovs method. Statistical deviations in propranolol pharmacokinetics were found in none of the three series. The most characteristic reactions to propranolol were BPav reductions in all series and HR decreases 2 hours after intake in the first and second series. These deviations were not pathologic but physiological variations typical of healthy people. Therefore, propranolol can be advised for rational pharmacotherapy of acute cardiovascular diseases in piloted space missions.


Subject(s)
Hypokinesia/blood , Hypokinesia/drug therapy , Propranolol/administration & dosage , Adult , Aerospace Medicine , Bed Rest , Cardiac Output/physiology , Heart Rate/physiology , Humans , Hypokinesia/pathology , Male , Middle Aged , Plethysmography, Impedance , Propranolol/blood , Propranolol/pharmacokinetics , Stroke Volume/physiology , Vascular Resistance/physiology
16.
J Chromatogr A ; 1418: 110-118, 2015 Oct 30.
Article in English | MEDLINE | ID: mdl-26422307

ABSTRACT

An Online post-column solvent-assisted ionization (OPSAI) method was developed for enhancing the ionization of the beta-blocker propranolol utilizing normal phase LC-MS/MS. Solvent-assisted electrospray ionization (SAESI) was studied by the introduction of the assistant solvents A: 0.5% Formic acid in Isopropanolol, B: 0.5% Formic acid in Isopropanolol-Water (1:1), and C: 0.5% Formic acid in water into the electrospray ionization chamber using a spray needle. Analyte molecules can be directly ionized by the aid of the assistant solvent spray. Both methods were applied to the chiral separation of propranolol enantiomers using normal phase analysis on cellulose-based chiral column. Interestingly, both methods are easy to handle and offer a wide range of assistant solvents that can be used in order to gain the optimum ionization of the analyte molecules. The both methods considerably improved the analyte signal and the peak area greatly increased. The propranolol average signal-to-noise (S/N) ratio was enhanced from 26±1 and 42±1 to 2341±61 and 1725±29 for R-propranolol and S-propranolol, respectively, when the post-column solvent method (OPSAI) was used with isopropanol-assistant solvent (A). While in case of solvent-assisted electrospray ionization method (SAESI) signal was enhanced from 26±1 and 42±1 to 2223±72 and 2155±58 for R-propranolol and S-propranolol, respectively, with water as an assistant solvent. The limit of detection was 10ng/mL and the method was linear in the range 50-2000ng/mL. The NPLC-MS method was applied for the determination of propranolol enantiomers in human plasma after microextraction by packed C18 sorbent.


Subject(s)
Adrenergic beta-Antagonists/blood , Propranolol/blood , Adrenergic beta-Antagonists/chemistry , Chromatography, Liquid/methods , Humans , Propranolol/chemistry , Solvents , Spectrometry, Mass, Electrospray Ionization/methods , Stereoisomerism , Tandem Mass Spectrometry/methods
17.
Pharmacol Rep ; 67(2): 339-44, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25712660

ABSTRACT

BACKGROUND: Diosmin is a natural flavone glycoside, a potent P-glycoprotein (P-gp) inhibitor in cultured cells and have the potential to alter the bioavailability of P-gp substrate drugs. However, the interaction between diosmin and fexofenadine is unreported. Hence, the present study was performed to investigate the effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine, a P-gp substrate in rats. METHODS: Fexofenadine intestinal transport and permeability were evaluated by in vitro non-everted sac and in situ single pass intestinal perfusion (SPIP) studies. These results were confirmed by an in vivo pharmacokinetic study of oral administered fexofenadine (10mg/kg) in rats. RESULTS: The intestinal transport and apparent permeability (Papp) of fexofenadine were significantly increased in duodenum, jejunum and ileum of diosmin pretreated group as compared with the control. Similarly effective permeability (Peff) of fexofenadine was increased significantly in ileum of diosmin pretreated group as compared with control. In comparison with control, pretreatment with diosmin significantly increased peak plasma concentration (Cmax) and area under the concentration-time curve (AUC), while there was no significant change was observed in half life (T1/2), time to reach peak plasma concentration (Tmax) and elimination rate constant (Kel) of fexofenadine. CONCLUSIONS: Diosmin significantly enhanced the oral bioavailability of fexofenadine by the inhibition of P-gp mediated drug efflux during the intestinal absorption. Co-administration of diosmin with fexofenadine can reduce the dosage and results in reduced side effects of fexofenadine. The clinical relevance of this interaction should be further evaluated in human subjects.


Subject(s)
Diosmin/pharmacology , Intestinal Absorption/drug effects , Terfenadine/analogs & derivatives , Administration, Oral , Animals , Biological Availability , Drug Interactions , Male , Permeability , Propranolol/blood , Propranolol/pharmacokinetics , Rats , Terfenadine/administration & dosage , Terfenadine/blood , Terfenadine/pharmacokinetics
18.
Talanta ; 134: 754-760, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25618732

ABSTRACT

Propranolol, a chiral drug with two configurations, i.e., (R)-propranolol hydrochloride (RPH) and (S)-propranolol hydrochloride (SPH), has racemes that can be used in clinical diagnosis due to their synergistic effects. SPH has a ß-receptor blocking effect, and RPH has an antiarrhythmic effect. In pH 4.6 Britton-Robinson (BR) buffer solution, both RPH and SPH can react with erythrosine B to form 1:1 ion-association complexes. In the SPH-Ery B reaction system, a remarkable enhancement of the resonance Rayleigh scattering (RRS) signal located at 338 nm was observed. However, a similar phenomenon was not obvious and was unstable in the RPH-Ery B reaction system. Based on this result, a simple, novel and sensitive method for the determination of SPH was proposed based on the RRS technique. The linear range and limit of detection were 0.0680~4.0 µg mL(-1) and 20.6 ng mL(-1), respectively. Additionally, the spectroscopic approaches of frequency doubling scattering (FDS) and second-order scattering (SOS) were also proposed for SPH detection in this article. The interaction information regarding the mechanism of the reaction, suitable reaction conditions, influencing factors and the effects of mixed solutions were our investigation aims. The method had been applied to the determination of SPH in fresh serum and urine samples of healthy human subjects with satisfactory results.


Subject(s)
Erythrosine/chemistry , Propranolol/analysis , Humans , Light , Propranolol/blood , Propranolol/chemistry , Propranolol/urine , Scattering, Radiation , Spectrum Analysis/methods
19.
Anal Chem ; 87(1): 754-9, 2015 Jan 06.
Article in English | MEDLINE | ID: mdl-25457985

ABSTRACT

A novel approach is described for the quantitative bioanalysis of drugs in blood samples by ionization of the analytes collected on solid-phase microextraction (SPME) fibers by mass spectrometry (MS). The technique combines the attractive features of SPME microsampling using minimal sample volumes with the speed, selectivity, and sensitivity capabilities of MS detection. The method reported in this study involved generating gas-phase ions directly from SPME fibers without the need for any additional sample preparation or chromatographic separation; the entire process was completed within 5 min. Traditionally, analytes extracted by SPME fibers are desorbed by washing with suitable solvents followed by a transfer into a sample vial and subsequent liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis to quantify the amount of analyte extracted and thereby determining the analyte concentration in the matrix. These sample preparation steps are completely eliminated by inserting the SPME fiber directly into the MS. Physiologically relevant concentrations of metoprolol and propranolol in blood samples were measured over several orders of magnitude down to concentration levels of 10 ng/mL. This preliminary assessment of direct SPME-MS showed high sensitivity (ng/mL), acceptable reproducibility (<30%), and lack of carryover. This novel approach simplifies current bioanalytical procedures providing time and cost savings. It demonstrates considerable potential for qualitative and quantitative pharmaceutical bioanalysis as well as other areas of challenging environmental and food analysis.


Subject(s)
Chromatography, Liquid/methods , Metoprolol/blood , Propranolol/blood , Solid Phase Microextraction/instrumentation , Solid Phase Microextraction/methods , Tandem Mass Spectrometry/methods , Animals , Rats
20.
Xenobiotica ; 45(4): 335-44, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25387586

ABSTRACT

1. Cytochrome P450 2D (CYP2D) protein is widely expressed across brain regions in human and rodents. We investigated the interactions between tramadol, a clinically used analgesic, and brain CYP2D regulators, by establishing concentration-time curves of tramadol and O-desmethyltramadol (M1) in rat cerebrospinal fluid (CSF) and plasma, as well as by analyzing the analgesia-time course of tramadol. 2. Propranolol (20 µg, intracerebroventricular injection), CYP2D inhibitor, prolonged the elimination t1/2 of tramadol (40 mg/kg, intraperitoneal injection) in the CSF; meanwhile, lower Cmax and AUC0-∞ values of M1 were observed. Nicotine (1 mg base/kg, subcutaneous injection, seven days), brain CYP2D inducer, induced a shorter Tmax and elevated Cmax of M1 in CSF. No differences in the peripheral metabolism of tramadol were observed following propranolol and nicotine pretreatment. Nicotine increased areas under the analgesia-time curve (AUC) for 0-45 min and 0-90 min of tramadol, which was attenuated by propranolol administration. The analgesic actions of tramadol positively correlated with cerebral M1 concentration. 3. The results suggest that the regulation of brain CYP2D by xenobiotics may cause drug-drug interactions (DDIs) of tramadol. Brain CYPs may play an important role in DDIs of centrally active substances.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Nicotine/pharmacokinetics , Propranolol/pharmacokinetics , Tramadol/pharmacokinetics , Animals , Brain/drug effects , Brain/metabolism , Chromatography, Liquid , Drug Interactions , Male , Nicotine/blood , Nicotine/cerebrospinal fluid , Propranolol/blood , Propranolol/cerebrospinal fluid , Rats , Tandem Mass Spectrometry , Tramadol/analogs & derivatives , Tramadol/blood , Tramadol/cerebrospinal fluid
SELECTION OF CITATIONS
SEARCH DETAIL
...